Biomaterials for Promoting Wound Healing in Diabetes

Juan Liu1,2, Huaiyuan Zheng3,4, Xinyi Dai1, Shicheng Sun1, Hans-Günther Machens1 and Arndt F Schilling1,4*

1Department of Plastic Surgery and Hand Surgery, Klinikum Rechts der Isar, Faculty of Medicine, Technische Universität München, Munich, Germany
2Department of Hand Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3Department of Cardiology, Klinikum Rechts der Isar, 1st Medicine Clinic, Technische Universität München, Munich, Germany
4Clinic for Trauma Surgery, Orthopaedic Surgery and Plastic Surgery, University Medical Center Göttingen, Germany

Abstract

Impaired wound healing is the leading cause of non-traumatic lower limb amputation in people with diabetes mellitus. Skin substitutes engineered from biomaterials currently play an important role in the healing process of diabetic wounds, especially those wounds that fail to show progress after standard wound care. This article summarizes current developments of biomaterials used for promoting the wound healing process in either diabetic animal models or patients with diabetes mellitus. Those biomaterials can be categorized into tissue-derived scaffolds, hydrogel-based biomaterials and biomaterials with controlled-release of signaling molecules. Tissue-derived scaffolds maintain perfect extracellular matrix architectures for three-dimensional cell growth and rebuilding of multi-layer tissue structures within scaffolds after implantation. Hydrogel-based biomaterials are engineered to resemble the natural extracellular matrix for cell invasion and capillary growth. Biomaterials processed with cells or controlled-release of signaling molecules (growth factors, cytokines) can induce angiogenesis, re-epithelialization, cell recruitment and migration as well as inhibit consistent inflammation, thereby accelerating the wound healing process. Better understanding of the mechanism of diabetic wound healing will lead to the development of even better biomaterials possibly with inclusion of engineered patient derived cells or factors which will aid in vivo vascularization and consistent release of tissue-inductive signals. By reviewing the recent literature, we draw future perspectives on new strategies for further improvement of the individualized therapy of diabetic wounds.

Keywords: Wound healing; Biomaterials; Scaffolds

Introduction

Impaired wound healing is the leading cause of amputation in people with diabetes mellitus [1]. It produces a high risk of recurrent hospitalization and has a long-term negative effect on quality of life, morbidity and mortality as well as on social economy [2,3]. Despite a relatively high standard in the treatment of chronic wounds, there still exists a high amputation rate. In diabetic wounds, due to infection and inflammation which lead to imbalance of protease and reactive oxygen species, essential growth factors are degraded, the ability of angiogenesis is impaired and cell recruitment to the wound sites is inhibited [4]. To facilitate wound healing and tissue regeneration in this situation, biomaterial-based scaffolds are currently widely used to provide extracellular matrix for cell invasion and capillary growth. Biomaterials processed with cells or controlled-release of signaling molecules (growth factors, cytokines) can induce angiogenesis, re-epithelialization, cell recruitment and migration as well as inhibit consistent inflammation, thereby accelerating the wound healing process. Better understanding of the mechanism of diabetic wound healing will lead to the development of even better biomaterials possibly with inclusion of engineered patient derived cells or factors which will aid in vivo vascularization and consistent release of tissue-inductive signals. By reviewing the recent literature, we draw future perspectives on new strategies for further improvement of the individualized therapy of diabetic wounds.

Type of Biomaterials Applied for Diabetic Wound Healing

According to the components of biomaterials, they can be categorized into three types: tissue-derived biomaterials, hydrogel-based biomaterials and biomaterials with controlled-release of signaling molecules (Figure 1 and Table 1).

Tissue-derived scaffolds

Scaffolds derived from tissues mimic the natural extracellular matrix substrates and provide three-dimensional natural structures as extracellular microenvironment for the cells. These valuable properties are frequently exploited for tissue engineering applications as well as for improvement of diabetic wound healing [5-7].

Those scaffolds can be processed from either cadaveric allografts of skin tissue, placenta tissue, porcine small intestinal submucosa (SIS) or from microalgae [8]. Cadaveric allograft is made from cadaveric human skin, in which the epidermis and cells are removed to avoid immunologic rejection [8]. Dehydrated Human Amnion/Chorion Membrane (DHACM) is composed of human amnion/chorion membrane, with a single layer of epithelial cells, a layer of basement membrane and an avascular connective tissue matrix to promote wound healing [9,10]. It has been reported to achieve wound closure faster than standard wound care. Cryopreserved micronized amnion (CPM) is a human wound matrix. It is able to provide fetal cells like MSCs, neonatal fibroblasts and epithelial cells as well as growth and angiogenic factors to the wound [11], however their respective contribution to the wound healing is still a matter of debate. Zheng et al. [12] applied cryopreserved living micronized amnion onto the wounds of db/db mice. They reported that the wound healing process was greatly promoted. They attribute this effect to secretion of growth factors, inflammation-related, and chemotaxis-related factors, which regulated migration of macrophages, recruitment of CD34+ progenitor cells, and neovascularization [12]. Porcine SIS is an acellular matrix derived from small intestinal submucosa of porcine, which showed positive effects on promoting diabetic wound healing [13]. Those tissue-derived scaffolds provide nearly perfect extracellular matrix architectures for three-
dimensional cell growth and rebuilding of multi-layer tissue structures within scaffolds after implantation, promoting tissue regeneration in diabetic wound healing processes.

**Hydrogel-based biomaterials**

Engineered hydrogels have the advantage over tissue derived matrices, that their properties can be changed more or less at will and that the ingredients are better defined. Usually they are engineered to resemble the extracellular matrix of natural soft tissues [14]. These biomaterials can be prepared as high-water-content hydrogels, sponge and patch structures or other architectures, processed by crosslinking, dehydration or freeze drying and electrospinning technique, respectively [15-17].

Poly-N-acetyl Glucosamine (pGlcNAc) is a matrix derived from microalgae, which is FDA approved for treating diabetic foot ulcers [18].

Fibrin is a common hydrogel used to fabricate scaffolds in the treatment of diabetic wounds [19]. It is able to enhance angiogenesis and modulate inflammation in the wound, which will accelerate the healing process. Integra is a collagen-glycosaminoglycan scaffold, which has been already applied in clinic for fibroblast and endothelial invasion and capillary growth [20]. It could also support epithelialization in the absence of vascularization. Lee et al. developed a nano-fibrous collagen/poly-D-L-lactide–glycolide (PLGA) scaffold membrane by electrospinning technique. This scaffold could be applied onto diabetic wounds and loaded with drugs, providing sustained release of glucophage and promoting wound closure [21].

In addition to biocompatible hydrogel scaffolds, cells play an important role in the process of wound healing by producing essential growth factors and inducing neovascularization. Therefore, cellularized scaffolds based on above biomaterials were developed for diabetic wound healing [22,23]. Navone et al. demonstrated electrospun nano-fibrous Silk fibroin patches cellularized with human adipose-derived mesenchymal stem cells (ADMSCs) as an effective treatment for wound healing, which improved skin regeneration in diabetic mice [24]. ADMSCs were reported to confer benefits as tissue restorative agents in vivo. This is ascribed to their own multi-linear differentiation properties as well as their ability to produce trophic factors for tissue regeneration [25,26]. O’Loughlin et al. seeded autologous early endothelial progenitor cells onto collagen scaffolds. They observed that cells exposed to osteopontin accelerated the speed of wound closure along with increased angiogenesis [27]. It was noted that the wound...
healing benefit was associated with a more efficient vascular network. Breibart et al. seeded mouse dermal fibroblasts onto polyglycolic acid scaffold matrices, on which the cells were retrovirally transduced with the human platelet-derived growth factor B (PDGF-B) gene [28]. Results showed accelerated wound healing in the group with PDGF-B transduced cells. Bilayered Living Cellular Construct (BLCC) is a FDA-approved product, which is engineered as bilayered collagen matrix with a dermal equivalent made of human neonatal foreskin fibroblasts and an epidermal equivalent made with human neonatal keratinocytes [29]. In randomized controlled trials, BLCC achieved closure in 56% of patients by 12 weeks compared with 38% of patients with standard wound care. Those hydrogel-based biomaterials provide a defined extracellular matrix for cell invasion, proliferation and vascularization, facilitating skin regeneration and angiogenesis in diabetic wounds.

Biomaterials with controlled-release of signaling molecules

In addition to the extracellular matrix support and biological effect provided by the biomaterial scaffolds, tissue-inductive signals for the cells that rebuild the skin are also essential. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have been shown to promote wound healing by inducing angiogenesis and inhibiting prolonged inflammation [24]. However, these molecules are degraded quite fast by enzymes existing in the protease-rich wound environment [30]. Therefore, researchers have developed controlled-release systems which are able to provide an efficient concentration of those functional molecules at the wound site during the healing process as well as protect the growth factors and cytokines from degradation and inactivation [31,32]. The release of the molecules was maintained by encapsulating nanoparticles, vectors (virus, plasmid, DNA, etc.) as well as preloading molecules within hydrogels during preparation [33–35].

Losi et al. developed a poly (ether)urethane–polydimethylsiloxane/ fibrin-based scaffold containing nanoparticles loaded with VEGF and bFGF. This scaffold induced complete re-epithelialization of the wound of diabetic mice, along with enhanced granulation tissue formation and collagen deposition [33]. Karri et al. impregnated curcumin loaded chitosan nanoparticles into collagen-alginate scaffolds for treating diabetic wounds [36], Breen et al. developed a fibrin scaffold for delivery of adenovirus encoding endothelial nitric oxide synthase (AdeNOS) to diabetic wounds [36]. Breen et al. developed a fibrin scaffold for delivery of a dermal equivalent made of human neonatal foreskin fibroblasts after implantation [36,37]. New strategies for in vivo vascularization before implantation and devices or systems for consistent releasing of tissue-inductive signals should be considered for future investigation. Antibacterial ability of biomaterials could also be created with a consistent releasing system. Developing new biomaterials on the basis of a better understanding of the underlying mechanisms will further promote diabetic wound healing. Advances in autologous cell therapy like iPSC (Induced pluripotent stem cell) technology and use of blood derived cells for autologous factor production may overcome the need of non-autologous cells/factors in the future, leading to optimized individualized therapy for diabetic wounds [38,39].

Conclusion and Future Perspectives

Chronic wounds in patients with diabetes mellitus are a major drain on the social economy, and are projected to play an even bigger role in the future. They result in a high risk of amputation, morbidity and mortality. According to the mechanism of impaired diabetic wound formation, tissue repair process and regeneration, biomaterials based on tissue-derived scaffolds, hydrogels as well as controlled-release growth factors and cytokines have been applied on diabetic wounds in research and clinical settings. Results showed positive effects on accelerating wound healing processes, by promoting angiogenesis, cell migration, re-epithelialization and tissue regeneration. However, the speed of vascularization of scaffolds, which occurred in vivo after implantation, might be insufficient to supply embedded cells within the first critical week. The level of tissue-induced molecular signals released from biomaterials is mainly dependent on the initial concentration and drops after implantation [36,37]. New strategies for in vivo vascularization before implantation and devices or systems for consistent releasing of tissue-inductive signals should be considered for future investigation. Antibacterial ability of biomaterials could also be created with a consistent releasing system. Developing new biomaterials on the basis of a better understanding of the underlying mechanisms will further promote diabetic wound healing. Advances in autologous cell therapy like iPSC (Induced pluripotent stem cell) technology and use of blood derived cells for autologous factor production may overcome the need of non-autologous cells/factors in the future, leading to optimized individualized therapy for diabetic wounds [38,39].

References

1. Siltanen OI, Niskanen LK, Laasko M, Siltanen JT, Pyörälä K (1993) Lower-extremity amputations in diabetic and non-diabetic patients. A population-based study in eastern Finland. Diabetes Care 16: 16-20.
2. Siersva Y, Thorsen H, Holstein PE, Kars M, Apelqvist J, et al. (2014) Health-related quality of life predicts major amputation and death, but not healing, in people with diabetes presenting with foot ulcers: the Eurodiaule study. Diabetes Care 37: 694-700.
3. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, et al. (2006) Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 45: S1-66.
4. Blaktny R, Jude E (2008) The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 23: 594-608.
5. Chen RN, Ho HO, Tsai YT, Sheu MT (2004) Process development of an acellular dermal matrix (ADM) for biomedical applications. Biomaterials 25: 2679-2686.
6. Cheng HW, Tsai YK, Cheung KM, Chan D, Chan BP, et al. (2009) Decellularization of chondrocyte-encapsulated collagen microspheres: a three-dimensional model to study the effects of acellular matrix on stem cell fate. Tissue Eng Part C Methods 15: 597-706.
7. Song JJ, Ott HC (2011) Organ engineering based on decellularized matrix scaffolds. Trends Mol Med 17: 424-432.
8. Hughes OB, Rakosi A, Macquhae F, Herskovitz I, Fox JD, et al. (2016) A review of cellular and acellular matrix products: Indications, techniques and outcomes. Plast Reconstr Surg 138: 138S-47S.
9. Johnson EL, Marshall JT, Michael GM (2016) A comparative outcomes analysis evaluating clinical effectiveness in two different human placental membrane products for wound management. Wound Repair Regen.
10. Massie M, Chinn K, Lim JJ, Godwin L, Young CS, et al. (2016) Type I and II diabetic adipose-derived stem cells respond in vitro to dehydrated human amnion/chorion membrane allograft treatment by increasing proliferation, migration and altering cytokine secretion. Adv Wound Care (New Rochelle) 5: 43-54.
11. Gibbons GW (2015) Grafix®, a cryopreserved placental membrane, for the treatment of chronic/infected wounds. Adv Wound Care (New Rochelle) 4: 534-544.
12. Zheng Y, Ji S, Wu H, Tian S, Zhang Y, et al. (2017) Topical administration of cryopreserved living micromized amnion accelerates wound healing in diabetic mice by modulating local microenvironment. Biomaterials 113: 56-67.
13. Guest JF, Weidlich D, Singh H, La Fontaine J, Garrett A, et al. (2017) Cost-effectiveness of using adjunctive porcine small intestine submucosa tri-layer matrix compared with standard care in managing diabetic foot ulcers in the US. J Wound Care 26: S12-S24.
14. Liu J, Zheng H, Poh PS (2015) Hydrogels for engineering of perfusable vascular networks. Int J Mol Sci 16: 15897-16016.
15. Chen S, Shi J, Zhang M, Chen Y, Wang X, et al. (2015) Mesenchymal stem cell-laden anti-inflammatory hydrogel enhances diabetic wound healing. Sci Rep 5: 18104.
16. Tong C, Hao H, Xia L, Liu J, Ti D, et al. (2016) Hypoxia pretreatment of bone marrow-derived mesenchymal stem cells seeded in a collagen-chitosan sponge scaffold promotes skin wound healing in diabetic rats with hind limb ischemia. Wound Repair Regen 24: 45-56.
17. Lai HJ, Kuan CH, Wu HC, Tsai JC, Chen TM, et al. (2014) Tailored design of electrospun composite nanofibers with staged release of multiple angiogenic growth factors for chronic wound healing. Acta Biomater 10: 4156-4166.
18. Pietramaggiore G, Yang HJ, Scherer SS, Kaipainen A, Chan RK, et al. (2008) Effects of poly-N-acetyl glucosamine (pGlCNac) patch on wound healing in db/db mouse. J Trauma 64: 803-808.
19. Kulkarni M, O'Loughlin A, Vazquez R, Mashayekhi K, Rooney P, et al. (2014) Use of a fibrin-based system for enhancing angiogenesis and modulating inflammation in the treatment of hyperglycemic wounds. Biomaterials 35: 2001-2010.
20. Jeschke MG, Rose C, Angle P, Füchtmeier B, Nerlich MN, et al. (2004) Development of new reconstructive techniques: use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds. Plast Reconstr Surg 113: 525-530.
21. Lee CH, Chang SH, Chen WJ, Hung KC, Lin YH, et al. (2015) Augmentation of diabetic wound healing and enhancement of collagen content using nanofibrous glucophage-loaded collagen/PLGA scaffold membranes. J Colloid Interface Sci 439: 88-97.
22. Assi R, Foster TR, He H, Stamat K, Bai H, et al. (2016) Delivery of mesenchymal stem cells in biomimetic engineered scaffolds promotes healing of diabetic ulcers. Regen Med 11: 245-260.
23. Zeng Y, Zhu L, Han Q, Liu W, Mao X, et al. (2015) Preformed gelatin microcryogels as injectable cell carriers for enhanced skin wound healing. Acta Biomater 25: 291-303.
24. Navone SE, Pascucci L, Dossena M, Ferri A, Invernici G, et al. (2014) Decellularized silk fibroin scaffold primed with adipose mesenchymal stromal cells improves wound healing in diabetic mice. Stem Cell Res Ther 5: 7.
25. Sorrell JM, Caplan Al (2010) Topical delivery of mesenchymal stem cells and their function in wounds. Stem Cell Res Ther 1: 30.
26. Nie C, Yang D, Xu J, Si Z, Jin X, et al. (2011) Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis. Cell Transplant 20: 205-216.
27. O'Loughlin A, Kulkarri M, Vaughan EE, Creane M, Liew A, et al. (2013) Autologous circulating angiogenic cells treated with osteopontin and delivered via a collagen scaffold enhance wound healing in the alloxan-induced diabetic rabbit ear ulcer model. Stem Cell Res Ther 4: 158.
28. Breitbart AS, Laster J, Parrett D, Porti D, Grant RT, et al. (2003) Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg 51: 409-414.
29. Steinberg JS, Edmonds M, Hurley DP Jr, King WN (2010) Confirmatory data from EU study supports Aplicare for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc 100: 73-77.
30. McCarty SM, Percival SL (2013) Proteases and delayed wound healing. Adv Wound Care (New Rochelle) 2: 438-447.
31. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, et al. (1999) Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors. Wound Repair Regen 7: 442-452.
32. Jazwa A, Kucharzewska P, Leja J, Zagorska A, Sierpniowska A, et al. (2010) Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice. Genet Vaccines Ther 8: 6.
33. Losi P, Briganti E, Errico C, Lisella A, Sanguineti E, et al. (2013) Fibrin-based scaffold incorporating VEGF- and bFGF-loaded nanoparticles stimulates wound healing in diabetic mice. Acta Biomater 9: 7814-7821.
34. Tokatliyan T, Carn C, Segura T (2015) Porous hyaluronic acid hydrogels for localized nonviral DNA delivery in a diabetic wound healing model. Adv Healthc Mater 4: 1084-1091.
35. Yin H, Ding G, Shi X, Guo W, Ni Z, et al. (2016) A bioengineered drug-Eluting scaffold accelerated cutaneous wound healing in diabetic mice. Colloids Surf B Biointerfaces 145: 226-231.
36. Karri VV, Kuppusamy G, Talluri SV, Mannemala SS, Kollipara R, et al. (2016) Curcumin loaded chitosan nanoparticles impregnated into collagen-alginate scaffolds for diabetic wound healing. Int J Biol Macromol 93: 1519-1529.
37. Breen AM, Dockery P, O'Brien T, Pandit AS (2008) The use of therapeutic gene eNOS delivered via a fibrin scaffold enhances wound healing in a compromised wound model. Biomaterials 29: 3143-3151.
38. Hadipanayi E, Schilling AF (2013) Hypoxia-based strategies for angiogenic induction: The dawn of a new era for ischemia therapy and tissue regeneration. Organogenesis 9: 281-272.
39. Hadipanayi E, Schilling AF (2014) Regeneration through autologous hypoxia preconditioned plasma. Organogenesis 10: 164-169.